Dulce Fontoura

Dulce Fontoura

Auto-generated profile, based on publicly available information

Dulce Fontoura

Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
NHNazha Hamdani
Nazha Hamdani
CFConstantijn Franssen
Constantijn Franssen
ALAndré Lourenço
André Lourenço
IFInês Falcão-Pires
Inês Falcão-Pires
DFDulce Fontoura
Dulce Fontoura
WPWalter J. Paulus
Walter J. Paulus
Background—: Obesity and diabetes mellitus are important metabolic risk factors and frequent comorbidities in heart failure with preserved ejection fraction. They contribute to myocardial diastolic dysfunction (DD) through collagen deposition or titin modification. The relative importance for myocardial DD of collagen deposition and titin modification was investigated in obese, diabetic ZSF1 rats after heart failure with preserved ejection fraction development at 20 weeks. Methods and Results—: Four groups of rats (Wistar-Kyoto, n=11; lean ZSF1, n=11; obese ZSF1, n=11, and obese ZSF1 with high-fat diet, n=11) were followed up for 20 weeks with repeat metabolic, renal, and echocardiographic evaluations and hemodynamically assessed at euthanization. Myocardial collagen, collagen cross-linking, titin isoforms, and phosphorylation were also determined. Resting tension (F passive )–sarcomere length relations were obtained in small muscle strips before and after KCl–KI treatment, which unanchors titin and allows contributions of titin and extracellular matrix to F passive to be discerned. At 20 weeks, the lean ZSF1 group was hypertensive, whereas both obese ZSF1 groups were hypertensive and diabetic. Only the obese ZSF1 groups had developed heart failure with preserved ejection fraction, which was evident from increased lung weight, preserved left ventricular ejection fraction, and left ventricular DD. The underlying myocardial DD was obvious from high muscle strip stiffness, which was largely (±80%) attributable to titin hypophosphorylation. The latter occurred specifically at the S3991 site of the elastic N2Bus segment and at the S12884 site of the PEVK segment. Conclusions—: Obese ZSF1 rats developed heart failure with preserved ejection fraction during a 20-week time span. Titin hypophosphorylation importantly contributed to the underlying myocardial DD.

15 June 2015 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
SLSara Leite
Sara Leite
JOJosé Oliveira-Pinto
José Oliveira-Pinto
MTMarta Tavares-Silva
Marta Tavares-Silva
MAMahmoud Abdellatif
Mahmoud Abdellatif
DFDulce Fontoura
Dulce Fontoura
ALAndré Lourenço
André Lourenço
Inclusion of exercise testing in diagnostic guidelines for heart failure with preserved ejection fraction (HFpEF) has been advocated, but the target population, technical challenges, and underlying pathophysiological complexity raise difficulties to implementation. Hemodynamic stress tests may be feasible alternatives. Our aim was to test Trendelenburg positioning, phenylephrine, and dobutamine in the ZSF1 obese rat model to find echocardiographic surrogates for end-diastolic pressure (EDP) elevation and HFpEF. Seventeen-week-old Wistar-Kyoto, ZSF1 lean, and obese rats ( n = 7 each) randomly and sequentially underwent (crossover) Trendelenburg (30°), 5 μg·Kg−1·min−1 dobutamine, and 7.5 μg·Kg−1·min−1 phenylephrine with simultaneous left ventricular (LV) pressure-volume loop and echocardiography evaluation under halogenate anesthesia. Effort testing with maximum O2 consumption (V̇o2 max) determination was performed 1 wk later. Obese ZSF1 showed lower effort tolerance and V̇o2 max along with higher resting EDP. Both Trendelenburg and phenylephrine increased EDP, whereas dobutamine decreased it. Significant correlations were found between EDP and 1) peak early filling Doppler velocity of transmitral flow (E) to corresponding myocardial tissue Doppler velocity (E′) ratio, 2) E to E-wave deceleration time (E/DT) ratio, and 3) left atrial area (LAA). Diagnostic efficiency of E/DT*LAA by receiver-operating characteristic curve analysis for elevation of EDP above a cut-off of 13 mmHg during hemodynamic stress was high (area under curve, AUC = 0.95) but not higher than that of E/E′ (AUC = 0.77, P = 0.15). Results in ZSF1 obese rats suggest that noninvasive echocardiography after hemodynamic stress induced by phenylephrine or Trendelenburg can enhance diagnosis of stable HFpEF and constitute an alternative to effort testing.

1 March 2012 in International Journal of Cardiology
Verified
Journal Article
Open access
ALAndré Lourenço
André Lourenço
DFDulce Fontoura
Dulce Fontoura
THTiago Henriques-Coelho
Tiago Henriques-Coelho
AMAdelino Leite Moreira
Adelino Leite Moreira
Pulmonary hypertension (PH), increasingly recognized as a major health burden, remains underdiagnosed due mainly to the unspecific symptoms. Pulmonary arterial hypertension (PAH) has been extensively investigated. Pathophysiological knowledge derives mostly from experimental models. Paradoxically, common non-PAH PH forms remain largely unexplored. Drugs targeting lung vascular tonus became available during the last two decades, notwithstanding the disease progresses in many patients. The aim of this review is to summarize recent advances in epidemiology, pathophysiology and management with particular focus on associated myocardial and systemic compromise and experimental therapeutic possibilities. PAH, currently viewed as a panvasculopathy, is due to a crosstalk between endothelial and smooth muscle cells, inflammatory activation and altered subcellular pathways. Cardiac cachexia and right ventricular compromise are fundamental determinants of PH prognosis. Combined vasodilator therapy is already mainstay for refractory cases, but drugs directed at these new pathophysiological pathways may constitute a significant advance. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

1 April 2014 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
DFDulce Fontoura
Dulce Fontoura
JOJosé Oliveira-Pinto
José Oliveira-Pinto
MTMarta Tavares-Silva
Marta Tavares-Silva
SLSara Leite
Sara Leite
FVFrancisco Vasques-Nóvoa
Francisco Vasques-Nóvoa
AMAdelino Leite Moreira
Adelino Leite Moreira
Endothelin-1 antagonists are increasingly used in the treatment of pulmonary hypertension despite the lack of knowledge of their myocardial and systemic effects. We assessed the right ventricular myocardial and systemic effects of endothelin-1 antagonists in monocrotaline-induced pulmonary hypertension. Male Wistar rats (180-200 g, n=57) randomly received 60 mg/kg monocrotaline or vehicle subcutaneously. Two days later, bosentan was randomly started (300 mg/kg/day) by oral route in a subgroup of monocrotaline-injected rats, while the other monocrotaline-injected and control rats received vehicle. At 25-30 days, invasive hemodynamic assessment was performed under anesthesia, arterial blood samples were collected for gas analysis and plasma was extracted for quantification of endothelin-1, cytokines, nitrates and 6-keto-prostaglandin F1α. Right ventricular myocardium was collected for assessment of cyclooxygenase and nitric oxide synthase activity and gene expression. The monocrotaline group developed pulmonary hypertension, low cardiac output, right ventricular hypertrophy and dilation, changes in gene expression and inflammatory activation that were attenuated in the group treated with bosentan. From a functional point of view, this group had improved right ventricular function and preserved ventriculo-vascular coupling, without deterioration in arterial gas parameters or systemic hypotension. In molecular terms, they showed reduced endothelin-1 and cytokine levels, decreased right ventricular inducible nitric oxide synthase and cyclooxygenase-2 activity and increased nitrate plasma levels compared with the non-treated group. In this study we demonstrate that besides attenuating pulmonary hypertension, bosentan has beneficial hemodynamic, myocardial and anti-inflammatory effects.

1 November 2011 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
ALAndré Lourenço
André Lourenço
FVFrancisco Vasques-Nóvoa
Francisco Vasques-Nóvoa
DFDulce Fontoura
Dulce Fontoura
CBCarmen Brás-Silva
Carmen Brás-Silva
RRRoberto Roncon-Albuquerque
Roberto Roncon-Albuquerque
AMAdelino Leite Moreira
Adelino Leite Moreira
Western-type diets (WD) constitute risk factors for disease but may have distinct effects in heart failure (HF) with cardiac cachexia (CC). We evalua

18 January 2008 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
SOS. Oliveira
S. Oliveira
HSHugo Sousa
Hugo Sousa
ASA.M. Santos
A.M. Santos
DPD. Pinto
D. Pinto
APA.L. Pinto‐Correia
A.L. Pinto‐Correia
Rui MedeirosRui Medeiros
Rui Medeiros